A simple, precise, sensitive and validated reverse-phase high performance liquid chromatographic (RP-HPLC) method was developed for the simultaneous estimation of rosuvastatin and ezetimibe in human plasma. The method involved protein precipitation and extraction of both drugs from plasma using acetonitrile and then separation on a C-18 column. Both the analytes were detected at a wavelength of 240 nm using diode array detector. Mobile phase for the said separation consists of a mixture of 1.5% phosphoric acid and acetonitrile in 30:70, v/v ratio. Linearity was in the range of 0.32-267 mg/mL for rosuvastatin and 0.08-67 mg/mL for ezetimibe with coefficient of determination between 0.9997 and 0.9967. Limit of detection was 0.106 mg/mL for rosuvastatin and 0.026 mg/mL for ezetimibe whereas limit of quantification was 0.32 mg/mL and 0.08 mg/mL for rosuvastatin and ezetimibe respectively. Recovery of both the analytes was greater than 75% with RSD less than 15 %. The total run time was less than five min for the two components. The developed method can be fruitfully employed for the determination of these two drugs in human plasma. 1-INTRODUCTION-enoic acid and a competitive inhibitor of HMG-CoA reductase [1][2]. It is used in the treatment of hypercholesterolemia and dyslipidemia [3][4]. Rosuvastatin is very effective in reducing low density lipoprotein cholesterol [5] and many studies have demonstrated its efficacy greater than other drugs of its class such as atorvastatin, simvastatin and pravastatin [5][6][7]. During literature review many methods were found reporting separation of rosuvastatin like capillary zone electrophoresis [8], Spectrophotometry [9-10] and HPLC [11][12][13][14].formulations.We are currently engaged in the development of simple HPLC methods for the determination of binary combinations of different classes of drugs including antihyperlipidemic drugs [21,22,[36][37][38][39][40][41][42][43][44][45][46]. The present work was therefore planned to develop a simple HPLC method to determine rosuvastatin and ezetimibe simultaneously in human plasma. During this study, a simple, economic and sensitive HPLC method with run time less than five min was developed in human plasma. The developed method have superiority over the Varghese et al method in that its linear range is 0.32-267 mg/mL for rosuvastatin and 0.08-67 mg/mL for ezetimibe and also the method is applied for human plasma. The method could have the potential to be used for any sort of studies planned for conducting in human plasma. Literature survey also revealed some analytical methods for the simultaneous determination of rosuvastatin and ezetimibe. These include spectrophotometry [30][31], HPTLC [32], Micellar liquid chromatography [33] and simultaneous equation method [34]. Recently Varghese et al [35] reported an RP-HPLC method for the simultaneous determination of rosuvastatin and ezetimibe. The method has some limitations as its linear range were narrow and have high detection limits of 0.5µg/mL for both drugs. Secondly the ...

The title compound, C12H10BrN3O3S, crystallizes with two crystallographically independent mol­ecules in the asymmetric unit. The dihedral angles between the two six-membered rings in the mol­ecules are 34.1 (3) and 45.1 (2)°. In the crystal structure, mol­ecules are connected via N—H⋯O and N—H⋯N hydrogen bonding.

In the title compound, C15H16N2O5S2, the dihedral between the two aromatic rings is 81.33 (6)°. In the crystal, pairs of N—H⋯O hydrogen bonds link the mol­ecules into centrosymmetric dimers, which are further connected via N—H⋯O hydrogen bonds into a chain running along [01].